Journal
RADIOLOGY AND ONCOLOGY
Volume 48, Issue 3, Pages 289-292Publisher
ASSOC RADIOLOGY & ONCOLOGY
DOI: 10.2478/raon-2013-0076
Keywords
childhood; non-Hodgkin lymphoma; folate pathway; polymorphism; high-dose methotrexate; toxicity
Funding
- Slovenian Research Agency (ARRS) [P1-0170, P3-0343]
Ask authors/readers for more resources
Background. We evaluated the influence of folate pathway polymorphisms on high-dose methotrexate (HD-MTX) related toxicity in paediatric patients with T-cell non-Hodgkin lymphoma (NHL). Patients and methods. In total, 30 NHL patients were genotyped for selected folate pathway polymorphisms. Results. Carriers of at least one MTHFR 677T allele had significantly higher MTX area under the time-concentration curve levels at third MTX cycle (P = 0.003). These patients were also at higher odds of leucopoenia (P = 0.006) or thrombocytopenia (P = 0.041) and had higher number of different HD-MTX-related toxicity (P = 0.035) compared to patients with wild-type genotype. Conclusions. Our results suggest an important role of MTHFR 677C>T polymorphism in the development of HD-MTX-related toxicity in children with NHL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available